Navigation Links
CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis

LA JOLLA, Calif., Feb. 17, 2011 /PRNewswire/ -- CalciMedica, a biotechnology company developing small molecules to treat inflammatory and autoimmune diseases, today announced that it has dosed the first cohort in a Phase 1 clinical trial of CM2489. CM2489 is a first-in-class calcium-release activated calcium (CRAC) channel inhibitor being studied as a once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.  In addition, the company announced that this milestone has triggered an additional $6 million tranche of financing from all existing investors, which include Sanderling Ventures, SR One and Biogen Idec New Ventures. The current financing will enable CalciMedica to complete its ongoing Phase 1 clinical trial by third quarter 2011.  

The randomized, placebo-controlled, blinded, single-ascending dose study is being conducted at a single site in the US under an Investigational New Drug (IND) application recently allowed by the FDA and will enroll 48 healthy volunteers through multiple cohorts. The goal of the study is to determine the safety, tolerability and pharmacokinetic profile of CM2489 in humans and to select doses for investigation in subsequent studies.

The CRAC channel activates a signaling pathway that is essential for the adaptive immune response in T cells. The therapeutic value of inhibiting this pathway has been established by calcineurin inhibitors, a class of immunosuppressants that work downstream from the CRAC channel.

"CM2489 is the first CRAC channel inhibitor, or CCI, to be tested in humans. CCIs have the potential to be safe and effective drugs to treat multiple chronic inflammatory and autoimmune diseases," said Gonul Velicelebi, Ph.D., president and CEO of CalciMedica. "We are targeting psoriasis as our first proof-of-concept indication and are considering rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, asthma, and multiple sclerosis for our follow-on indications."

"CRAC channels have been a drug target sought by the pharmaceutical industry for many years. These channels and the discovery of selective inhibitors that can safely modulate the immune system have been elusive," said Peter McWilliams, Ph.D., chairman of the CalciMedica board of directors and managing director at Sanderling Ventures.  "The team at CalciMedica has done a phenomenal job of identifying the channel components, discovering small molecules that inhibit the channel and bringing this pioneering approach into the clinic."

About CalciMedica

CalciMedica, a privately-held small molecule discovery and development company, has a portfolio of first-in-class drug candidates that inhibit the calcium-release activated calcium (CRAC) channel and that have the potential to treat chronic inflammatory and autoimmune diseases. The company's lead drug candidate, CM2489, is under development for the treatment of moderate-to-severe plaque psoriasis. The company has exclusive intellectual property rights to STIM and Orai proteins that constitute the CRAC channel as well as the novel compounds that inhibit the CRAC channel activity. CalciMedica's investors are Sanderling Ventures, SR One and Biogen Idec New Ventures.  For more information, visit

SOURCE CalciMedica
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CalciMedica Appoints Evelyn Graham to its Board of Directors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... . The Global ...
(Date:6/22/2016)... -- Research and Markets has announced the addition of ... offering. The global biomarkers ... in 2013. The market is expected to grow at a five-year ... increasing from $50.6 billion in 2015 to $96.6 billion in 2020. ... period (2015 to 2020) are discussed. As well, new products approved ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):